NTB Measure Gains Ground In Alzheimer's
This article was originally published in The Pink Sheet Daily
Executive Summary
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.
You may also be interested in...
The Alzheimer's Divide
Issues of clinical trial design are at the forefront in Alzheimer's drug development. Researchers and investors are weighing the impact of late-stage failures, even as significant unknowns remain about disease mechanism and the correlation of biochemical markers and clinical effects. A fundamental question hangs over AD drug development, which is unique in many respects: in deciding how to move from Phase II into Phase III, what can you know and how can you know it?
Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan
EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.
Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan
EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.